{"filings":[{"id":777718,"accession_number":"0001636282-26-000075","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-06-01T20:01:39+00:00","items":["8.01","9.01"],"status":"ready","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["License field expanded from inflammatory bowel disease to all human disease indications.","Monotherapy dosing for non-IBD indications restricted until June 1, 2030; combination until June 1, 2028.","Restrictions may terminate earlier upon a Material Transaction (change of control, asset sale) by June 1, 2028.","Paragon receives non-exclusive license under Spyre's cross-license patents for retained IL-23 antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748117,"accession_number":"0001636282-26-000056","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-05-29T20:45:58+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amended and restated 2016 ESPP (66.9M for, 45.5K against) at May 27 annual meeting.","Director Peter Harwin resigned effective May 27, 2026; Board reduced from 8 to 7 directors.","Elected Class I directors Mark McKenna, Cameron Turtle, and Laurie Stelzer to 2029 term.","Non-binding advisory vote on executive compensation passed with 62.1M for, 4.8M against.","Ratification of KPMG as independent auditor for FY2026 passed with 68.4M for, 670 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94272,"accession_number":"0001636282-26-000051","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).","Pro forma cash $1,176.8M as of March 31, 2026, including $435.3M net from April 2026 offering; runway into H2 2029.","SPY001 achieved primary endpoint in Part A of SKYLINE: RHI score reduction 9.2 points (p<0.0001); clinical remission 40%, endoscopic improvement 51%.","SPY001 safety consistent with α4β7 class; RA sub-study of SKYWAY over-enrolled, topline readout accelerated to Q3 2026.","On track for 6 proof-of-concept readouts in 2026 across SKYLINE and SKYWAY Phase 2 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94271,"accession_number":"0001628280-26-025508","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.","Proceeds to fund IBD and rheumatic disease programs, including preclinical, clinical trials, manufacturing, and Phase 3 readiness.","Underwriting agreement with Jefferies, Goldman Sachs, Evercore, and Guggenheim Securities as representatives.","Offering closed on April 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94270,"accession_number":"0001628280-26-024906","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Spyre reports preliminary $741M cash; suspends ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.","Includes $30M legacy asset disposition proceeds; $23M expected to be paid to CVR holders in Q2 2026.","Effective April 13, 2026, terminated ATM prospectus; no further share sales under Sales Agreement until new filing.","Sales Agreement with TD Securities remains in force; company funded without current need for dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94269,"accession_number":"0001628280-26-024831","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.","Secondary endpoints: clinical remission 40%, endoscopic improvement 51%, Modified Mayo Score change -3.7.","Well tolerated: 6 TEAEs (14%), 1 SAE deemed not drug-related; no drug-related AEs or discontinuations.","Part A enrollment closed; Part B enrolling monotherapy (SPY001/002/003) and combination cohorts.","Proof-of-concept data expected mid-2026 for SPY002, Q3 2026 for SPY003; Part B data on track for 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106501,"accession_number":"0001636282-26-000022","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Therapeutics reports Q4 2025 net loss of $62.5M; cash $756.5M; Phase 2 readouts expected Q2/Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $62.5M (vs $56.3M Q4 2024); R&D expense $44.6M (vs $50.5M).","Cash, cash equivalents, and marketable securities $756.5M at Dec 31, 2025; raised $316.2M gross in Oct 2025 public offering.","On track for 6 proof-of-concept readouts in 2026: SKYLINE Part A (IBD) data expected Q2 2026; SKYWAY trial (RA, PsA, axSpA) data expected Q4 2026.","Appointed Kate Tansey Chevlen as Chief Commercial Officer.","Expected cash runway into second half of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106500,"accession_number":"0001193125-26-009894","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.","SPY001 enrollment complete ahead of schedule; SKYLINE Part A readouts now expected to begin Q2 2026.","Six total proof-of-concept readouts planned: 3 from SKYLINE (UC) and 3 from SKYWAY (RA, PsA, axSpA) by 4Q 2026.","Pro forma cash $783M as of Sept 30, 2025, including Oct 2025 offering net proceeds; runway into H2 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122845,"accession_number":"0001636282-25-000104","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.","SPY003 well tolerated, no serious adverse events; safety profile consistent with anti-IL-23 class.","Q3 2025 net loss of $11.2M, compared to $69.0M in Q3 2024; R&D expenses $45.2M.","Pro forma cash $782.7M as of Sep 30, 2025, including $296.5M net from October 2025 public offering.","Company expects 6 proof-of-concept readouts in 2026 from SKYLINE and SKYWAY Phase 2 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122844,"accession_number":"0001193125-25-240237","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.","Gross proceeds of approximately $316.2 million before underwriting discounts and expenses.","Net proceeds to fund IBD and rheumatic disease programs, including clinical trials and Phase 3 readiness.","Underwriters include Jefferies, TD Securities, Leerink Partners, and Stifel; offering closed Oct 15, 2025.","Offering was made under existing effective shelf registration statement (File No. 333-285341)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122843,"accession_number":"0001193125-25-237904","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.","Full Q3 2025 financial results not yet finalized; subject to completion of closing procedures.","Company cautions that final amount may differ materially from preliminary estimate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139547,"accession_number":"0001636282-25-000091","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.","Cash, equivalents, and marketable securities of $526.6M as of June 30, 2025; expected runway into H2 2028.","R&D expense rose to $40.1M from $32.6M YoY on higher clinical trial costs; recognized $10.0M gain on sale of legacy asset pegzilarginase.","Positive interim Phase 1 data for two anti-TL1A antibodies (SPY002/SPY072): well-tolerated, PK supports Q3M/Q6M dosing, full TL1A engagement to 20 weeks.","Initiated Phase 2 SKYLINE-UC platform in May; on track to start Phase 2 SKYWAY-RD basket study in Q3 2025; SPY003 Phase 1 data expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157119,"accession_number":"0001193125-25-141756","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.","SPY002 half-life ~75 days (≥3x first-gen anti-TL1As); supports quarterly or twice-yearly SC dosing.","Single 100 mg dose of either antibody suppressed free TL1A below LLOQ through 20 weeks.","SKYLINE-UC (UC) platform trial started May 2025; SKYWAY-RD basket (RA, PsA, axSpA) planned Q3 2025.","Expects 9 Phase 2 readouts by 2027; cash runway into H2 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157118,"accession_number":"0001636282-25-000063","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.","Advisory vote on executive compensation approved: 42.9M for, 3.1M against, 0.1M abstain, 3.1M broker non-votes.","Ratified KPMG LLP as independent auditor for FY2025: 49.2M for, 57k against, 9k abstain, no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157117,"accession_number":"0001636282-25-000050","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.","Net loss of $44.8M for Q1 2025 vs. $43.9M in Q1 2024; R&D expenses rose to $41.6M.","Extended Phase 1 data for SPY001 supports potential quarterly or biannual dosing; Phase 2 initiation planned mid-2025.","Interim Phase 1 data for SPY002 expected Q2 2025; first participant dosed in Phase 1 trial of SPY003.","Plan to initiate Phase 2 trials in UC and RA mid-2025 with 7+ proof-of-concept readouts in 2026-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175480,"accession_number":"0001193125-25-048423","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Spyre dismisses PwC as auditor, appoints KPMG; discloses material weakness in controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PwC dismissed as auditor effective Feb 28, 2025; KPMG appointed as new independent auditor for FY2025.","No disagreements with PwC on accounting principles; material weakness identified as of Dec 31, 2024 in controls over EPS calculation for convertible preferred stock.","Material weakness led to restatement of FY2023 consolidated financial statements.","PwC's reports for FY2024 and FY2023 were unqualified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175479,"accession_number":"0001636282-25-000022","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.","Raised $230M in November 2024 public offering; Q4 net cash used in operations $37.2M.","Interim Phase 1 data for SPY001 (α4β7) shows half-life >90 days supporting Q6M dosing; Phase 2 UC trial mid-2025.","SPY002 (TL1A) Phase 1 interim data expected Q2 2025; Phase 2 RA trial initiation mid-2025; top-line 2026.","SPY003 (IL-23) FIH trial starts Q1 2025 with interim data H2 2025; Phase 2 platform trial mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175478,"accession_number":"0001193125-25-005015","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.","Phase 1 interim data for SPY002 (TL1A) expected 2Q2025; SPY003 (IL-23) Phase 1 interim data in 2H2025.","Phase 2 platform trial in UC launching mid-2025 with SPY001, SPY002, SPY003, and combinations; initial open-label data mid-2026.","SPY002 expansion into rheumatoid arthritis; Phase 2 RA trial start mid-2025 with topline results in 2026.","SPY001 Phase 1 data showed half-life >90 days, supporting quarterly to twice-annual subcutaneous dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192437,"accession_number":"0001628280-24-048527","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.","Gross proceeds expected to be approximately $200M before expenses; net proceeds plus existing cash expected to fund operations into H2 2028.","Underwriters: Jefferies, Goldman Sachs, Evercore, Guggenheim; closing expected Nov 20, 2024.","Offered pursuant to Form S-3 shelf registration; prospectus supplement filed Nov 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192436,"accession_number":"0001636282-24-000105","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["4.02","8.01"],"status":"ready","headline":"Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.","Common stock net loss per share changed for all affected periods; e.g., Q3 2024 revised from ($1.36) to ($1.06).","Series A Preferred stock EPS restated (e.g., Q3 2024: ($42.22) vs. not previously reported).","Material weakness in internal controls over financial reporting identified; remediation plan to be filed.","No impact on cash position or other financial data; amendments to prior filings expected soon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192435,"accession_number":"0001628280-24-046860","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.","No serious adverse events; all adverse events mild; no Grade 2+ TEAEs; no trial discontinuations.","Complete α4β7 receptor saturation maintained through Day 57 with single 300mg dose.","Phase 2 UC platform trial expected to start mid-2025; ~500 subjects, 12-week induction + 38-week maintenance.","Portfolio maintenance dosing guidance updated to Q3M-Q6M for monotherapies and combinations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192434,"accession_number":"0001636282-24-000085","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.","Cash, cash equivalents and marketable securities of $414.2M as of Sep 30, 2024; runway extended well into 2027.","SPY001 Phase 1 interim data expected by year-end 2024; SPY002 FIH trials initiated in Q4 2024.","Appointed Sheldon Sloan, M.D., as Chief Medical Officer, effective October 2024.","Preclinical data for SPY003 at UEGW showed >3-fold half-life extension vs risankizumab; FIH accelerated to Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192433,"accession_number":"0001193125-24-237150","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.","Preclinical data at UEGW shows comparable potency to risankizumab with >3x half-life extension in NHPs (~30 days).","Licensed IL-23 antibodies from Paragon for up to $22M in development/regulatory milestones plus low single-digit royalties.","Portfolio includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.","Combination data shows synergy of anti-IL-23 with anti-TL1A or anti-α4β7 in reducing IL-17 and inflammation in models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208903,"accession_number":"0001636282-24-000058","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K/A","filed_at":"2024-08-08T23:59:59+00:00","items":[],"status":"ready","headline":"Spyre Therapeutics files 8-K/A to correct date on cover page of prior filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amendment corrects clerical error on cover page date of Original 8-K filed August 7, 2024.","No changes to financial results, disclosures, or exhibits from the original report.","Original 8-K reported Q2 2024 financials; this filing only revises the report date.","No new material information for investors; purely administrative correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208904,"accession_number":"0001636282-24-000053","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.","R&D expenses increased to $32.6M (vs $17.4M) driven by IBD pipeline advancement; no acquired IPR&D in Q2 2024.","SPY001 (anti-α4β7) Phase 1 dosing initiated; interim proof-of-concept data expected by end of 2024 for every-8-12 week dosing.","SPY002 (anti-TL1A) two candidates with subnanomolar potency; FIH trials in H2 2024 with interim data in H1 2025.","SPY003 (anti-IL-23) development candidate nominated; FIH trial expected in H1 2025; $426M cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226710,"accession_number":"0001193125-24-150395","cik":1636282,"company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["As of May 29, 2024, common shares outstanding: 50,782,384.","Pro forma shares (incl. Series A & B preferred conversion): ~65.3 million.","Conversion of Series B Preferred was effective per prior 8-K filed May 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6296859046.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}